Top Non-alcoholic Steatohepatitis Biomarkers Companies

Global Non-alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.67 Billion in 2025 to USD 12.59 Billion by 2033, growing at a CAGR of 28.7% during the forecast period (2026–2033).

The global market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Non-alcoholic Steatohepatitis Biomarkerss. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions. 'Genfit SA (France) ', 'Gilead Sciences, Inc. (United States) ', 'Novartis AG (Switzerland) ', 'Pfizer Inc. (United States) ', 'Siemens Healthineers AG (Germany) ', 'Bio-Rad Laboratories, Inc. (United States) ', 'Abbott Laboratories (United States) ', 'Prometheus Laboratories Inc. (United States) ', 'NGM Biopharmaceuticals, Inc. (United States) ', 'Metabolon, Inc. (United States) ', 'Perspectum Ltd (United Kingdom) ', 'Precision Medicine Group, Inc. (United States) ', 'Grifols, S.A. (Spain) ', 'Hologic, Inc. (United States) ', 'Quest Diagnostics Incorporated (United States) ', 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Biopredictive (France)'

One driver of the global NASH biomarkers market is the increasing prevalence of NASH worldwide. NASH is a liver disease characterized by the accumulation of fat in the liver, leading to inflammation and damage. The rising incidence of obesity, sedentary lifestyle, and unhealthy dietary habits are contributing to the growing prevalence of NASH. As a result, there is a need for effective biomarkers that can accurately diagnose NASH, monitor disease progression, and assess treatment response. The demand for NASH biomarkers is driven by the growing awareness of the disease and the need for better diagnostic tools.

One key market trend in the market is the increasing focus on non-invasive diagnostic techniques. As NASH is a complex and progressive liver disease, early and accurate diagnosis is crucial for effective management and treatment. Non-invasive biomarkers, such as blood-based tests and imaging techniques, offer advantages over invasive liver biopsies, including lower patient discomfort, reduced costs, and wider accessibility. The development and adoption of non-invasive biomarkers for NASH diagnosis are gaining traction, driven by the need for reliable and convenient diagnostic tools. This trend is expected to enhance patient outcomes, streamline clinical trials, and drive the growth of the global NASH biomarkers market.

One dominant region in the global non-alcoholic steatohepatitis (NASH) biomarkers market is North America. North America has a well-established healthcare infrastructure, advanced diagnostic technologies, and a high prevalence of NASH, making it a key region for NASH biomarker research and development. The region is home to several major pharmaceutical and biotechnology companies that are actively involved in developing and commercializing NASH biomarkers. Additionally, North America has a strong regulatory framework and reimbursement policies that support the adoption of biomarker-based diagnostics in clinical practice.